Similar articles

• Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia.

  Orlowski RZ, Mills SR, Hartley EE, Ye X, Piantadosi S, Ambinder RF, Gore SD, Miller CB. Orlowski RZ, et al. Leuk Lymphoma. 2004 Nov;45(11):2215-9. doi: 10.1080/10428190410001733763. Leuk Lymphoma. 2004. PMID: 15512809 Clinical Trial.
• Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation.

  Dignani MC, Mykietiuk A, Michelet M, Intile D, Mammana L, Desmery P, Milone G, Pavlovsky S. Dignani MC, et al. Bone Marrow Transplant. 2002 Feb;29(3):263-7. doi: 10.1038/sj.bmt.1703354. Bone Marrow Transplant. 2002. PMID: 11859400 Clinical Trial.
• A possible pitfall in acyclovir prophylaxis for recurrent herpetic keratitis?

  James SH, Prichard MN. James SH, et al. J Infect Dis. 2013 Nov 1;208(9):1353-5. doi: 10.1093/infdis/jit379. Epub 2013 Jul 30. J Infect Dis. 2013. PMID: 23901076 No abstract available.
• [Antiviral resistance of herpes simplex virus and varicella-zoster virus].

  Daikoku T, Shiraki K. Daikoku T, et al. Nihon Rinsho. 2007 Feb 28;65 Suppl 2 Pt. 1:480-6. Nihon Rinsho. 2007. PMID: 17455667 Review. Japanese. No abstract available.
• [Contribution of the laboratory in case of resistance to acyclovir of herpes simplex and varicella zoster virus].

  Morfin F, Frobert E, Thouvenot D. Morfin F, et al. Ann Biol Clin (Paris). 2003 Jan-Feb;61(1):33-40. Ann Biol Clin (Paris). 2003. PMID: 12604384 Review. French.